2013-08-26 09:48:15
Seasonal allergies are a common problem for many, with symptoms ranging from slightly bothersome to debilitating. Many sufferers often reach for the common over the counter antihistamines not realizing alternatives exist that work as effectively without some of the unpleasant side effects that these over the counter drugs often entail. Common butterbur (Petasites hybridus) is one such alternative with very positive clinical research backing up its use in humans. Standardized extract from the butterbur plant has been studied and shown to be as effective in alleviating allergy symptoms as Fexofenadine, commonly known as Allegra(1) and Cetirizine, commonly known as Zyrtec or Reactin.(2) One study looking at the mechanism of action gave patients two tablets three times a day of the standardized extract of butterbur and found after 5 days not only significant improvement in nasal symptoms but also found decreased levels of histamine and leukotrienes in the blood (both chemicals involved in the inflammatory reactions of asthma and allergies).(3) Similarly it has shown promise as a natural alternative treatment for asthma.(4) Common dosage of butterbur extract for seasonal allergies is 1-2 tablets of the standardized extract, 8 mg Petasins, 2-6 times daily. Based on the research thus far it appears well tolerated and without the sedative effects normally experienced with antihistamines.
References
1. Schapowal A. Treating intermittent allergic rhinitis: a prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze339. Phytother Res. 2005; 19 (6):530-7.
2. Schapowal A. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ. 2002; 324(7330):144-6.
3. Thomet OA, Schapowal A, Heinisch IV, Wiesmann UN, Simon HU. Anti-inflammatory activity of an extract of Petasites hybridus in allergic rhinitis. Int Immunopharmacol. 2002; 2(7): 997-1006.
4. Danesch UC. Petasites hybridus (Butterbur root) extract in the treatment of asthma – an open trial. Altern Med Rev. 2004; 9(1):54-62.